These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21570283)

  • 1. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Kim HJ; Kwak WY; Min JP; Lee JY; Yoon TH; Kim HD; Shin CY; Kim MK; Choi SH; Kim HS; Yang EK; Cheong YH; Chae YN; Park KJ; Jang JM; Choi SJ; Son MH; Kim SH; Yoo M; Lee BJ
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3809-12. PubMed ID: 21570283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibitor with β-amino amide scaffold: synthesis, SAR and biological evaluation.
    Kim HJ; Kwak WY; Min JP; Sung SY; Kim HD; Kim MK; Kim HS; Park KJ; Son MH; Kim SH; Lee BJ
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5545-9. PubMed ID: 22850208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of thiouracil derivatives as dipeptidyl peptidase IV inhibitors.
    Sharma M; Singh D; Gupta M
    Chem Biol Drug Des; 2013 Feb; 81(2):257-64. PubMed ID: 23039850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of β-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors.
    Park WS; Kang SK; Jun MA; Shin MS; Kim KY; Rhee SD; Bae MA; Kim MS; Kim KR; Kang NS; Yoo SE; Lee JO; Song DH; Silinski P; Schneider SE; Ahn JH; Kim SS
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1366-70. PubMed ID: 21306895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.
    Ammirati MJ; Andrews KM; Boyer DD; Brodeur AM; Danley DE; Doran SD; Hulin B; Liu S; McPherson RK; Orena SJ; Parker JC; Polivkova J; Qiu X; Soglia CB; Treadway JL; VanVolkenburg MA; Wilder DC; Piotrowski DW
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1991-5. PubMed ID: 19275964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor.
    Gupta RC; Chhipa L; Mandhare AB; Zambad SP; Chauthaiwale V; Nadkarni SS; Dutt C
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5021-5. PubMed ID: 19643608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (3R)-3-amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide as a potent dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Nitta A; Fujii H; Sakami S; Nishimura Y; Ohyama T; Satoh M; Nakaki J; Satoh S; Inada C; Kozono H; Kumagai H; Shimamura M; Fukazawa T; Kawai H
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5435-8. PubMed ID: 18819797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.
    Sutton JM; Clark DE; Dunsdon SJ; Fenton G; Fillmore A; Harris NV; Higgs C; Hurley CA; Krintel SL; MacKenzie RE; Duttaroy A; Gangl E; Maniara W; Sedrani R; Namoto K; Ostermann N; Gerhartz B; Sirockin F; Trappe J; Hassiepen U; Baeschlin DK
    Bioorg Med Chem Lett; 2012 Feb; 22(3):1464-8. PubMed ID: 22177783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors.
    Tsai TY; Hsu T; Chen CT; Cheng JH; Chiou MC; Huang CH; Tseng YJ; Yeh TK; Huang CY; Yeh KC; Huang YW; Wu SH; Wang MH; Chen X; Chao YS; Jiaang WT
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1908-12. PubMed ID: 19269819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Design, synthesis and in vitro activity of glycinamide-bearing compounds as DPP-IV inhibitors].
    Han B; Huan Y; Lin ZY; Li P; Shen ZF; Yin DL; Huang HH
    Yao Xue Xue Bao; 2010 Nov; 45(11):1379-84. PubMed ID: 21361038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potent dipeptidyl peptidase IV inhibitors derived from β-aminoamides bearing substituted [1,2,3]-triazolopiperidines for the treatment of type 2 diabetes.
    Shan Z; Peng M; Fan H; Lu Q; Lu P; Zhao C; Chen Y
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1731-5. PubMed ID: 21334204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors.
    Wang L; Zhang B; Ji J; Li B; Yan J; Zhang W; Wu Y; Wang X
    Eur J Med Chem; 2009 Aug; 44(8):3318-22. PubMed ID: 19375196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [(S)-gamma-(4-Aryl-1-piperazinyl)-l-prolyl]thiazolidines as a novel series of highly potent and long-lasting DPP-IV inhibitors.
    Yoshida T; Sakashita H; Akahoshi F; Hayashi Y
    Bioorg Med Chem Lett; 2007 May; 17(9):2618-21. PubMed ID: 17317162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.
    Zhang Z; Wallace MB; Feng J; Stafford JA; Skene RJ; Shi L; Lee B; Aertgeerts K; Jennings A; Xu R; Kassel DB; Kaldor SW; Navre M; Webb DR; Gwaltney SL
    J Med Chem; 2011 Jan; 54(2):510-24. PubMed ID: 21186796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Mattei P; Boehringer M; Di Giorgio P; Fischer H; Hennig M; Huwyler J; Koçer B; Kuhn B; Loeffler BM; Macdonald A; Narquizian R; Rauber E; Sebokova E; Sprecher U
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1109-13. PubMed ID: 20031405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.
    Banno Y; Miyamoto Y; Sasaki M; Oi S; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Tsubotani S; Tani A; Funami M; Tawada M; Yamamoto Y; Aertgeerts K; Yano J; Maezaki H
    Bioorg Med Chem; 2011 Aug; 19(16):4953-70. PubMed ID: 21764322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
    Yeh TK; Tsai TY; Hsu T; Cheng JH; Chen X; Song JS; Shy HS; Chiou MC; Chien CH; Tseng YJ; Huang CY; Yeh KC; Huang YL; Huang CH; Huang YW; Wang MH; Tang HK; Chao YS; Chen CT; Jiaang WT
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3596-600. PubMed ID: 20483603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
    Maezaki H; Banno Y; Miyamoto Y; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Sasaki M; Tsubotani S; Tani A; Funami M; Yamamoto Y; Tawada M; Aertgeerts K; Yano J; Oi S
    Bioorg Med Chem; 2011 Aug; 19(15):4482-98. PubMed ID: 21741847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
    Deng J; Peng L; Zhang G; Lan X; Li C; Chen F; Zhou Y; Lin Z; Chen L; Dai R; Xu H; Yang L; Zhang X; Hu W
    Eur J Med Chem; 2011 Jan; 46(1):71-6. PubMed ID: 21106276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.